STAT3 Dominant-Negative Disease Studies

NIAID clinical trial volunteer signs an informed consent form, acknowledging that he understands the study protocol as well as possible risks and benefits associated with his participation.

Credit: NIAID

STAT3 dominant-negative disease (STAT3DN)—also known as autosomal dominant hyper-IgE syndrome (AD-HIES) or Job’s Syndrome—has widespread deleterious effects on patients’ health. NIAID-supported research seeks to determine the effect of STAT3DN on the immune system, including which immune cells and responses are affected and how these abnormalities translate into patients’ symptoms.

Current Clinical Research Studies Seeking Volunteers

The following are selected clinical trials supported by NIAID and investigating topics related to STAT3DN. The links lead to full study descriptions, eligibility criteria and contact information.

00-I-0159: Study of Clinical Features and Genetics of Hyperimmunoglobulin E Recurrent Infection

This study is enrolling patients and families with a confirmed or suspected diagnosis of a hyper-immunoglobulin E syndrome (HIES), including STAT3DN, for extensive phenotypic and genotypic study as well as disease management. Findings from this study may help identify further genetic etiologies and gain a better understanding of the pathogenesis of HIES.

01-I-0202: Study of Mycobacterial Infections

This study is enrolling people with STAT3DN, cystic fibrosis, and non-tuberculous mycobacterial (NTM) infections to compare the features of these diseases, which all involve recurrent infections of the lungs and possibly other organs.

Read about NIAID research on STAT3 dominant-negative disease.

Content last reviewed on